Valeant names interim CEO in Pearson’s absence
January 6, 2016Medical Communications, Sales and Marketing Valeant
Valeant has named company director Howard Schiller as interim chief executive officer to serve while full-time boss Michael Pearson is …
The case for adaptive trials in dementia
January 6, 2016Manufacturing and Production, Research and Development Alzheimer's, Alzheimer's disease, adaptive trials, research
An ageing population and widespread chronic neuro-degenerative disease will make dementia an ever increasing burden on society, families and the …
Roche teams with DH for drug repurposing trial
January 6, 2016Research and Development DH, NIHR, Off Patent Drugs Bill, Off-Patent Drugs Bill, RoActemra, Roche, drug repurposing, tocilizumab
Roche and the UK Department of Health have launched a trial, to explore whether one of the company’s treatments for …
Takeda and Enterome collaborate on new therapeutics for stomach disorders
January 6, 2016Research and Development Enterome, Takeda, gastrointestinal, inflammatory bowel syndrome, irritable bowel syndrome
Takeda and Enterome Bioscience have entered a drug discovery collaboration to research and develop potential new therapeutics for disorders including …
MSD chooses partner to develop ‘game-changing’ cancer therapies
January 6, 2016Research and Development CPABs, Cancer, Cell-Penetrating Alphabodies, Complix, MSD, autoimmune diseases
MSD has entered a research collaboration with biopharma company Complix, using the company’s proprietary technology to develop new treatments for …
Sanofi abandons MannKind’s failed inhalable insulin
January 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin
Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …
Gilead success in late-stage hepatitis B trials
January 5, 2016Research and Development, Sales and Marketing Gilead, hepatitis B, phase III
Two Phase III trials evaluating Gilead treatments in chronic hepatitis B virus (HBV) infection have met their primary objectives, showing …
Eli Lilly predicts revenue growth in 2016
January 5, 2016Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales
Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …
BioMarin elects former Allergan CEO to board
January 5, 2016Medical Communications, Research and Development, Sales and Marketing
BioMarin Pharmaceutical has announced the election of former Allergan chief executive, David Pyott, to the company’s board of directors. Pyott served …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Bayer and Baxalta in separate €1 billion-plus deals
January 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ascensia diabetes care, Baxalta, Bayer, diabetes, panasonic, symphogen
Baxalta has signed a deal with Symphogen potentially worth as much as €1.4 billion, under which the companies will develop …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Merck’s Erbitux approved for NHS Wales
January 5, 2016Manufacturing and Production, Sales and Marketing Erbitux, Merck, cetuximab, colorectal cancer, metastatic colorectal cancer
The All Wales Medicines Strategy Group has recommended Merck’s Erbitux in combination with chemotherapy for restricted use in the NHS …
Novartis’ Cosentyx shows benefits in Phase III AS trials
January 4, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Secukinumab, ankylosing spondylitis
Novartis says results from two Phase III studies for Cosentyx in ankylosing spondylitis (AS) showing significant clinical improvements versus placebo.Results …
Former Merck R&D expert joins RedX Pharma board
January 4, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing RedX Pharma
Dr Bernhard Kirschbaum, 57, has been added as a non-executive director at RedX Pharma with immediate effect. Kirschbaum is a …
Reports: $32bn Shire takeover of Baxalta close to done deal
January 4, 2016Sales and Marketing Baxalta, Shire, acquisition, merger
The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to …
‘Rejuvenated’ pharma manufacturing set for 2016 comeback
January 4, 2016Manufacturing and Production, Sales and Marketing Employment, industry, manufacturing, patent cliff, pharma, production
The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in …
Takeda and Teva set out generics joint venture plan
January 4, 2016Sales and Marketing Takeda, Teva, generics, joint venture
Takeda and Teva have detailed plans for a new joint venture to create a new company to market off-patent generic …
KaloBios files for bankruptcy after Shkreli arrest
January 4, 2016Sales and Marketing KaloBios, Martin Shkreli
KaloBios has filed for bankruptcy in the wake of chief executive Martin Shkreli’s arrest on securities fraud charges last month …
Season’s greetings from Pharmafocus
December 25, 2015Merry Christmas and a happy new year from all at Pharmafocus!We will be back on Monday 4 January with all …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
